Hemovent Files Two Additional Patent Applications for its Portable ECMO Device for Both Circulatory and Respiratory Support

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

How To Control a Radio Frequency (RF) Process

The radio frequency welding and manufacturing process uses electromagnetic energy and pressure to fuse and permanently bond vinyl, thermoplastic, and coated materials to produce a specific product - all according to customer requirements. Using this RF sealing process, a distinct, one-piece perpetual bond is formulated that is both solid and resistant to ripping or tearing. But how is this process controlled, and with what specific tools? Read on.

March 22, 2017

Hemovent GmbH, an emerging medical device company, announced today that it has filed two additional patents, for a gas exchanger and a pump—related to its novel and portable ExtraCorporeal Membrane Oxygenation (ECMO) device.

“Although ECMO has proven to be an effective treatment for acute respiratory and circulatory failure, and although our system’s portability is very likely to expand the use of ECMO, we fully expect that our Hemovent system will mitigate many device-related complications in standard ECMO, such as hemolysis, that manifest due to flow-pressure rate issues and blood-clotting as a result of stagnant flow and insufficient washout zones,” said Oliver Marseille, Ph.D., co-founder and chief technology officer.

“We believe Hemovent’s ECMO system is designed for superior blood-handling and more consistently superior patient outcomes compared to standard ECMO,” added Dr. Marseille. “For these reasons, we expect that when Hemovent is available by mid-2018 it will drive ECMO usage not only for applications such as Extracorporeal Cardio Pulmonary Resuscitation (ECPR) but also as an effective therapy for other cardiac and respiratory failure indications.”

Dr. Marseille was a co-founder of CircuLite® (HeartWare® International) prior to co-founding Hemovent—which is developing the world’s smallest and first self-contained, fully portable ECMO system designed to support or replace heart and lung function in the event of cardiac and respiratory failure.



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.